Papzimeos™

Drug - Papzimeos™ (zopapogene imadenovec-drba) [Precigen, Inc.]

August 2026

Therapeutic Area - Recurrent respiratory papillomatosis (RRP)

Approval criteria

Patient must meet an age-appropriate medically accepted indication, as defined in Section 1927 of the Social Security Act, for the requested agent; AND
Patient has a confirmed histological diagnosis of recurrent respiratory papillomatosis with HPV 6 or HPV 11; AND
Surgical debulking of any present visible papilloma will be performed prior to the initial, third and fourth injections; AND
Patient has the presence of laryngotracheal papillomas; AND
Patient has required three or more interventions (e.g., surgery, systemic therapy) in the last 12 months for control of respiratory papilloma; AND
Prescriber has reviewed Papzimeos Warnings/Precautions and will monitor patient status as appropriate.
Duration of approval is 6 months (180 days) for 4 doses total and cannot be renewed

1 dose (5 x 1011 particle units [PU] per dose) on day 1, day 12, week 6 and week 12 and may not be renewed

Papzimeos must be billed as a professional claim

Provider Call Center: (844) 575-7887